Saluda Medical, Inc. (ASX:SLD)
Australia · Delayed Price · Currency is AUD | Market Cap | 117.19M |
| Revenue (ttm) | 114.04M +242.1% |
| Net Income | -378.77M |
| EPS | -9.84 |
| Shares Out | 252.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 436,734 |
| Average Volume | 917,458 |
| Open | 0.4600 |
| Previous Close | 0.4650 |
| Day's Range | 0.4500 - 0.4800 |
| 52-Week Range | 0.4450 - 2.6500 |
| Beta | n/a |
| RSI | 26.39 |
| Earnings Date | May 1, 2026 |
About Saluda Medical
Saluda Medical, Inc., a medical device company, develops Evoke, an investigational device for the neuromodulation industry in the United States, Australia, the United Kingdom, and the Netherlands. The company develops a closed-loop spinal cord stimulation system that measures the spinal cord's response to stimulation and adjusts on every pulse to optimize activation within the patient's therapeutic window. It also offers an application to sense, measure, and adjust the pulse. The company was founded in 2011 and is based in Bloomington, Minnesot... [Read more]
Financial Performance
In fiscal year 2025, Saluda Medical's revenue was $70.36 million, an increase of 36.13% compared to the previous year's $51.68 million. Losses were -$149.30 million, 52.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Saluda Medical Earnings Call Transcript: Q3 2026
Q3 saw 34% year-over-year revenue growth, driven by a 55% increase in U.S. patient implants and strong international performance. FY 2026 revenue guidance was raised to $87 million, with gross margin improvements expected from new product launches and operational efficiencies.
Saluda Medical Earnings release: Q3 2026
Saluda Medical released its Q3 2026 earnings on April 30, 2026, summarizing the period's financial results.
Saluda Medical Transcript: NWR Virtual Healthcare Conference
Saluda presented its closed-loop spinal cord stimulation technology, highlighting strong clinical outcomes, reduced therapy burden, and significant U.S. market expansion. Financial results show accelerating revenue, improved gross margins, and increased guidance for fiscal 2026.
Saluda Medical Earnings Call Transcript: H1 2026
Revenue grew 17% year-over-year to $39.4M in H1 FY26, with gross margin up to 49.4% and strong U.S. and international growth. FY26 revenue guidance reaffirmed at $85M, with improved cash burn and adjusted EBITDA expected.
Saluda Medical Quarterly report: H1 2026
Saluda Medical has published its H1 2026 quarterly earnings report on February 25, 2026.
Saluda Medical Earnings release: Q2 2026
Saluda Medical released its Q2 2026 earnings on January 27, 2026, summarizing the period's financial results.
Saluda Medical Slides: Q2 2026
Saluda Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 27, 2026.
Saluda Medical Transcript: Investor update
Raised AUD 231 million and began ASX trading to fund U.S. commercial expansion. Closed-loop spinal cord stimulation technology offers strong clinical outcomes, low therapy burden, and significant market opportunity, with a focus on rapid sales force growth and new reimbursement models.
Saluda Medical Slides: Investor update
Saluda Medical has posted slides in relation to its latest quarterly earnings report, which was published on December 3, 2025.